OXFORD - Rapid adoption by pharmaceutical companies of new drug discovery technologies can endanger the future of platform companies unless they learn to adapt to the new environment.

Although it started life as a gene sequencing company, Lion Bioscience AG, which originally stood for Laboratories for the Investigation of Nucleotide sequences, has changed tack gently twice in the two and half years since its formation. First it morphed into a bioinformatics company, and now has transformed into a bio-information technology company in a bid to find the course for prolonged sustainability.